Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Original Biomedicals CoROCO:6483 40 EV-to-EBIT is -8.59 as of Sep. 05, 2026. GuruFocus rates ROCO:6483 with a GF Score™ of 40/100. The stock has 3 warning signs investors should review. Among 682 Drug Manufacturers companies, Original Biomedicals Co ranks worse than 146627.42% on this metric.
Original Biomedicals Co (ROCO:6483) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Original Biomedicals Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$873.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Original Biomedicals Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-101.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Original Biomedicals Co EV-to-EBIT Related Terms
Original Biomedicals Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Original Biomedicals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Original Biomedicals Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Original Biomedicals Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Original Biomedicals Co's EV-to-EBIT falls into.
Original Biomedicals Co's current Enterprise Value is NT$873.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Original Biomedicals Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-101.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Original Biomedicals Co (ROCO:6483) has a EV-to-EBIT of -8.59 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Original Biomedicals Co and its competitors. According to the industry distribution chart, Original Biomedicals Co ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Original Biomedicals Co's EV-to-EBIT too high?
Original Biomedicals Co's current EV-to-EBIT is -8.59. Based on the distribution chart, Original Biomedicals Co ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Original Biomedicals Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Original Biomedicals Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Original Biomedicals Co ranks #999999 out of 682 companies for EV-to-EBIT. This places Original Biomedicals Co in the lower half of its industry. The industry median EV-to-EBIT is 15.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Original Biomedicals Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Original Biomedicals Co's current EV-to-EBIT is -8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Original Biomedicals Co stock overvalued right now?
Original Biomedicals Co (ROCO:6483) has a current EV-to-EBIT of -8.59. The current EV-to-EBIT is -8.59. Original Biomedicals Co's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Original Biomedicals Co (ROCO:6483), the current EV-to-EBIT is -8.59 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Original Biomedicals Co Ltd is a biopharmaceutical company engaged in the research and development of drugs. The company focuses on developing new drug formulations, drug delivery systems, and repurposing existing pharmaceutical products.
40GF Score
Get the complete analysis for ROCO:6483
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6483 has been successfully added to your 
